Lncrnas for therapy and diagnosis of cardiac hypertrophy

Abstract

The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

1 - 15 . (canceled) 
     
     
         16 . A method of treatment of pathological cardiac hypertrophy and/or reducing the risk of pathological cardiac hypertrophy in a subject, by administering to said subject a pharmaceutical composition comprising a compound for promoting expression and/or activity of the long non-coding RNA (lncRNA) H19. 
     
     
         17 . The method according to  claim 16 , wherein the compound is:
 (a) a nucleic acid sequence which comprises or consists of the nucleic acid sequence encoding H19,   (b) an expression vector expressing the nucleic acid sequence as defined in (a), or   (c) a host comprising the expression vector of (b).   
     
     
         18 . The method according to  claim 16 , wherein the expression of the nucleic acid sequence is under the control of a heart-specific promoter. 
     
     
         19 . The method according to  claim 16 , wherein the cardiac hypertrophy is a ventricular hypertrophy. 
     
     
         20 . The method according to  claim 16 , wherein the cardiac hypertrophy is a left ventricular hypertrophy. 
     
     
         21 . The method according to  claim 16 , wherein the cardiac hypertrophy is a right ventricular hypertrophy. 
     
     
         22 . The method according to  claim 17 , wherein the host is a prokaryotic or eukaryotic cell. 
     
     
         23 . The method according to  claim 22 , wherein the eukaryotic cell is a mammalian cell. 
     
     
         24 . The method according to  claim 16 , wherein the subject is human. 
     
     
         25 . The method according to  claim 16 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier or excipient. 
     
     
         26 . The method according to  claim 16 , wherein the compound promoting the expression and/or the activity of the lncRNA H19 is formulated as a vesicle. 
     
     
         27 . The method according to  claim 26 , wherein the vesicle is a liposome. 
     
     
         28 . The method according to  claim 27 , wherein the liposome is a cationic liposome. 
     
     
         29 . The method according to  claim 26 , wherein the vesicle is a polymer-based nanoparticle. 
     
     
         30 . The method according to  claim 16 , wherein the compound is formulated as an adenoviral vector (AAV) construct. 
     
     
         31 . The method according to  claim 30 , wherein the AAV construct is under the control of a heart-specific promoter. 
     
     
         32 . The method according to  claim 31 , wherein the heart-specific promoter is a troponin T promoter.